'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

Surging demand for weight loss and diabetes drugs leaves the pharmaceutical sector at risk from a “bubble effect” as profitability soars, new research suggests. Demand for the likes of Wegovy and Zepbound has driven research and development returns to their highest level in years, but a report published by Deloitte on Monday suggests this is…

Read Full News

Netflix’s 'Beef' highlights a $5,000 deductible — how to handle your own healthcare costs

A still from Netflix’s ‘Beef.’ Courtesy: Netflix In the new season of the Netflix comedy-drama, “Beef,” Ashley, played by Cailee Spaeny, lands in the hospital due to an ovarian cyst. The waiting area is bleak, with gray decor and patients who look like they’ve been stranded there for years. Ashley’s partner, Austin, played by Charles…

Read Full News

Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again. The pharmaceutical giant now expects 2026 revenue to come in between $82 billion and $85 billion, up from…

Read Full News